home / stock / gnmsf / gnmsf quote
Last: | $278.342 |
---|---|
Change Percent: | -3.46% |
Open: | $293.74 |
Close: | $278.342 |
High: | $293.89 |
Low: | $274.16 |
Volume: | 810 |
Last Trade Date Time: | 05/08/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$278.342 | $293.74 | $278.342 | $293.89 | $274.16 | 810 | 05-08-2024 |
$283.92 | $283.92 | $283.92 | $294.63 | $283.92 | 577 | 05-07-2024 |
$296.59 | $285.91 | $296.59 | $296.59 | $285.91 | 255 | 05-06-2024 |
$289.744 | $295 | $289.744 | $301.366 | $282.69 | 375 | 05-03-2024 |
$276.47 | $287.03 | $276.47 | $287.03 | $272.95 | 160 | 05-02-2024 |
$272.81 | $272.81 | $272.81 | $284.99 | $272.81 | 161 | 05-01-2024 |
$274.22 | $274.22 | $274.22 | $284.63 | $274.22 | 120 | 04-30-2024 |
$272.05 | $285.43 | $272.05 | $285.43 | $272.05 | 497 | 04-29-2024 |
$274.35 | $274.35 | $274.35 | $288.15 | $269.75 | 626 | 04-26-2024 |
$269.87 | $269.87 | $269.87 | $283.58 | $265.3 | 314 | 04-25-2024 |
$279.6 | $279.24 | $279.6 | $290.4 | $275.55 | 1,217 | 04-24-2024 |
$290.34 | $280.41 | $290.34 | $294.54 | $279.36 | 343 | 04-23-2024 |
$289.67 | $279.76 | $289.67 | $290.528 | $279.76 | 5,321 | 04-22-2024 |
$284.55 | $287.06 | $284.55 | $288.3 | $283.3 | 241 | 04-19-2024 |
$290.38 | $281.08 | $290.38 | $290.38 | $279.82 | 217 | 04-18-2024 |
$281.02 | $282.2 | $281.02 | $292.85 | $278.65 | 212 | 04-17-2024 |
$285.11 | $295.94 | $285.11 | $295.94 | $285.11 | 417 | 04-16-2024 |
$282.004 | $295.59 | $282.004 | $295.59 | $278.46 | 206 | 04-15-2024 |
$291.12 | $292.51 | $291.12 | $297.46 | $290.92 | 299 | 04-12-2024 |
$298.164 | $306.17 | $298.164 | $306.17 | $294.75 | 766 | 04-11-2024 |
News, Short Squeeze, Breakout and More Instantly...
Genmab A/S Dkk Company Name:
GNMSF Stock Symbol:
OTCMKTS Market:
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...
Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark;...
Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, financial performance for the year and the financial outlook for...